| Species |
Human |
| Protein Construction |
LRRC15/LIB (Tyr22-Gly538)
Accession # Q8TF66-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized AntiLRRC15 Antibody, hFc Tag at 5μg/ml (100μl/well) on the plate can bind LRRC15/LIB[Biotin], His & Avi, Human. Test result was comparable to standard batch. |
| Expression System |
CHO |
| Theoretical Molecular Weight |
60.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The chimeric protein binds in vitro and in vivo to a specific element upstream of LRRC15, leading to dramatic transcriptional activation. LRRC15 encodes a leucine-rich transmembrane protein, present at the leading edge of migrating cells, the expression of which in normal tissues is restricted to the invasive cytotrophoblast layer of the placenta; small interfering (siRNA)-mediated suppression of LRRC15 expression in breast cancer cells leads to abrogation of invasiveness in vitro. |
| Synonyms |
LIB; LRRC15 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
